Diabetes drug controls blood glucose, cardiac risk

July 19, 2005

A new review of studies confirms that the drug metformin should be in the first line of defense against type 2 diabetes.

Using metformin alone can improve control of blood glucose, while also reducing risk factors for heart disease such as excess body weight, cholesterol levels and hypertension, the review found.

The systematic evidence review included 29 trials comparing the benefits of metformin to placebo, dietary changes, other oral medications and insulin therapy. The studies comprised a total of 5,259 participants and had a minimum follow-up period of three months.

"This systematic review suggests the utility of metformin monotherapy as first-line therapy in the management of type 2 diabetes and ... the prevention of its vascular complications," say the authors, led by Dr. Antonio Saenz, an internist in Madrid. In type 2 diabetes, insulin produced by the pancreas is not able to get sugar from the blood into the body's energy-hungry cells. Metformin normalizes blood sugar by increasing uptake in the liver, muscle, fat, and other tissues. The review appears in the current issue of The Cochrane Library, a publication of The Cochrane Collaboration, an international organization that evaluates medical research. Systematic reviews draw evidence-based conclusions about medical practice after considering both the content and quality of existing medical trials on a topic. The review added more recent trials of metformin since completion of the landmark 1998 United Kingdom Prospective Diabetes Study (UKPDS), the largest and longest diabetes study undertaken to date. It focused on the same health outcomes as the earlier study: diabetes-related problems such as heart attack, stroke, kidney failure, nerve damage, amputation, blindness and death.

"The eight additional trials reporting primary outcomes do not change any of the conclusions of the UKPDS," conclude the review authors. "In overweight type 2 diabetics, intensive metformin shows more benefit than [other drugs] or insulin therapy, for reducing the risk for any clinical end point related to type 2 diabetes, all-cause mortality and stroke."

"Our review confirms that tight glycemic control with metformin monotherapy is one of the main therapeutic options in the type 2 diabetes mellitus in patients with overweight or obesity," they say. In addition, they confirm that the adverse effects of metformin, mainly on the digestive tract, are not life-threatening. Metformin first became available in Europe in 1979, but was not cleared for use in the United States until 1994 due to concerns about a potentially fatal complication called lactic acidosis. Diabetes takes a severe toll on blood vessels throughout the body, especially when combined with other cardiovascular risk factors. Two out of three people with diabetes die from heart disease and stroke, according to the American Diabetes Association.

"Diabetes management is more than control of blood glucose," advises the American Diabetes Association. "People with diabetes must also manage blood pressure and cholesterol and talk to their health provider to learn about other ways to reduce their chance for heart attacks and stroke."

The review notes that Dr. Saenz received an evidence-based health care award funded by Novartis, the manufacturer of metformin, but that the company did not have any influence on the review process or conclusions.
-end-
FOR MORE INFORMATION
Health Behavior News Service: 202-387-2829 or www.hbns.org.
Interviews: Antonio Saenz, tel: 34-913-524-030, email antoniosaenz@ya.com
To receive a full copy of the review, contact Julia Lampam at 44-124-377-0668 or jlampam@wiley.co.uk

Saenz A et al. Metformin Monotherapy for Type 2 Diabetes Mellitus. The Cochrane Database of Systematic Reviews 2005, Issue 3.

The Cochrane Collaboration is an international nonprofit, independent organization that produces and disseminates systematic reviews of health care interventions and promotes the search for evidence in the form of clinical trials and other studies of interventions. Visit http://www.cochrane.org for more information.

Center for Advancing Health

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.